Kiniksa(KNSA) - 2025 Q2 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals International, plc (Exact Name of Registrant as Specified in Its Charter) England and Wales 98-1795578 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) FORM 10-Q (Mark One) ☒ QUARTERLY REP ...